BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 19325518)

  • 1. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.
    Robak T; Korycka A; Lech-Maranda E; Robak P
    Molecules; 2009 Mar; 14(3):1183-226. PubMed ID: 19325518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
    Robak T; Lech-Maranda E; Korycka A; Robak E
    Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias.
    Robak T; Robak P
    Curr Pharm Des; 2012; 18(23):3373-88. PubMed ID: 22591387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Older and new purine nucleoside analogs for patients with acute leukemias.
    Robak P; Robak T
    Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications.
    Robak T; Korycka A; Kasznicki M; Wrzesien-Kus A; Smolewski P
    Curr Cancer Drug Targets; 2005 Sep; 5(6):421-44. PubMed ID: 16178817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel purine nucleoside analogues for hematological malignancies.
    Korycka A; Lech-Marańda E; Robak T
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
    Tallman MS; Hakimian D
    Blood; 1995 Oct; 86(7):2463-74. PubMed ID: 7670093
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2006 May; 6(5):575-81. PubMed ID: 16719832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
    Korycka A; Błoński JZ; Robak T
    Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purine analogues in the management of lymphoproliferative diseases.
    Johnson SA
    Clin Oncol (R Coll Radiol); 1996; 8(5):289-96. PubMed ID: 8934048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.
    Robak T
    Drugs Aging; 2005; 22(12):983-1012. PubMed ID: 16363884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purine nucleoside antimetabolites in development for the treatment of cancer.
    Parker WB; Secrist JA; Waud WR
    Curr Opin Investig Drugs; 2004 Jun; 5(6):592-6. PubMed ID: 15242246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purine nucleoside analogues in the treatment of myleoid leukemias.
    Robak T
    Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New nucleoside analogs for patients with hematological malignancies.
    Robak T
    Expert Opin Investig Drugs; 2011 Mar; 20(3):343-59. PubMed ID: 21320002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New prospects in the treatment of indolent lymphomas with purine analogues.
    Cheson BD
    Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S27-36. PubMed ID: 9672772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies.
    Spiers AS
    Blood Rev; 1987 Jun; 1(2):106-10. PubMed ID: 3332090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
    Saven A
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):31-3. PubMed ID: 7908757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.